Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

PCSK9 inhibitors may improve cardiovascular outcomes-Can we afford them?

Arbel R, Hammerman A, Triki N, Greenberg D.

Int J Cardiol. 2016 Oct 1;220:242-5. doi: 10.1016/j.ijcard.2016.06.126.

PMID:
27389448
2.

Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study.

Ellis MH, Neuman T, Bitterman H, Dotan SG, Hammerman A, Battat E, Eikelboom JW, Ginsberg JS, Hirsh J.

Eur J Intern Med. 2016 Sep;33:55-9. doi: 10.1016/j.ejim.2016.05.023.

PMID:
27296588
3.

The Esmo Magnitude of Clinical Benefit Scale for Novel Cancer Medicines - Correspondence with Prioritization Decisions In Updating the Israeli National List of Health Services.

Hammerman A, Greenberg-Dotan S, Feldhamer I, Birnbaum Y, Cherny NI.

Value Health. 2015 Nov;18(7):A336. doi: 10.1016/j.jval.2015.09.117. No abstract available.

4.

Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study.

Hammerman A, Greenberg-Dotan S, Feldhamer I, Bitterman H, Yerushalmi R.

PLoS One. 2015 Sep 16;10(9):e0138229. doi: 10.1371/journal.pone.0138229.

5.

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators..

N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489.

6.

Systemic Therapy for Psoriasis and the Risk of Herpes Zoster: A 500,000 Person-year Study.

Shalom G, Zisman D, Bitterman H, Harman-Boehm I, Greenberg-Dotan S, Dreiher J, Feldhamer I, Moser H, Hammerman A, Cohen Y, Cohen AD.

JAMA Dermatol. 2015 May;151(5):533-8. doi: 10.1001/jamadermatol.2014.4956.

PMID:
25797026
7.

The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study.

Hammerman A, Greenberg-Dotan S, Battat E, Feldhamer I, Bitterman H, Brenner B.

Acta Oncol. 2015 Feb;54(2):164-70. doi: 10.3109/0284186X.2014.958532.

PMID:
25350524
8.

Impact of a financial risk-sharing scheme on budget-impact estimations: a game-theoretic approach.

Gavious A, Greenberg D, Hammerman A, Segev E.

Eur J Health Econ. 2014 Jun;15(5):553-61. doi: 10.1007/s10198-013-0544-6.

PMID:
24326947
9.

Oncologists' and family physicians' views on value for money of cancer and congestive heart failure care.

Greenberg D, Hammerman A, Vinker S, Shani A, Yermiahu Y, Neumann PJ.

Isr J Health Policy Res. 2013 Nov 18;2:44. doi: 10.1186/2045-4015-2-44.

10.

Which is more valuable, longer survival or better quality of life? Israeli oncologists' and family physicians' attitudes toward the relative value of new cancer and congestive heart failure interventions.

Greenberg D, Hammerman A, Vinker S, Shani A, Yermiahu Y, Neumann PJ.

Value Health. 2013 Jul-Aug;16(5):842-7. doi: 10.1016/j.jval.2013.04.010.

11.

Trends in outpatient antibiotic use in Israel during the years 2000-2010: setting targets for an intervention.

Low M, Nitzan O, Bitterman H, Cohen C, Hammerman A, Lieberman N, Raz R, Balicer RD.

Infection. 2013 Apr;41(2):401-7. doi: 10.1007/s15010-012-0332-8.

PMID:
23001542
12.

[Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals].

Hammerman A, Greenberg D.

Harefuah. 2012 Jun;151(6):364-7, 376. Review. Hebrew.

PMID:
22991869
13.

Financial risk-sharing in updating the National List of Health Services in Israel: stakeholders' perceived interests.

Hammerman A, Feder-Bubis P, Greenberg D.

Value Health. 2012 Jul-Aug;15(5):737-42. doi: 10.1016/j.jval.2012.01.007.

14.

[Public financing for off-label use of drugs].

Hammerman A, Lipschitz Y, Pliskin J, Greenberg D.

Harefuah. 2011 Feb;150(2):163-7, 204. Hebrew.

PMID:
22164947
15.

[Why do good drugs disappear?].

Brezis M, Tomer R, Klang S, Hammerman A.

Harefuah. 2010 Oct;149(10):652-5, 683. Hebrew.

PMID:
21568061
16.

Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.

Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J.

Value Health. 2010 Jun-Jul;13(4):381-7. doi: 10.1111/j.1524-4733.2010.00724.x.

17.

Variability in outpatient antimicrobial consumption in Israel.

Nitzan O, Low M, Lavi I, Hammerman A, Klang S, Raz R.

Infection. 2010 Feb;38(1):12-8. doi: 10.1007/s15010-009-9065-8.

PMID:
20107859
18.

Early versus delayed, provisional eptifibatide in acute coronary syndromes.

Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK; EARLY ACS Investigators..

N Engl J Med. 2009 May 21;360(21):2176-90. doi: 10.1056/NEJMoa0901316.

19.

Antipsychotics and diabetes: an age-related association.

Hammerman A, Dreiher J, Klang SH, Munitz H, Cohen AD, Goldfracht M.

Ann Pharmacother. 2008 Sep;42(9):1316-22. doi: 10.1345/aph.1L015.

PMID:
18664607
20.

Supplemental Content

Loading ...
Support Center